2/4
07:00 am
dsnky
DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo
Low
Report
DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo
2/3
08:23 am
dsnky
Astra wins FDA priority review for Daiichi's Datroway; denied approval for lupus therapy [Seeking Alpha]
Low
Report
Astra wins FDA priority review for Daiichi's Datroway; denied approval for lupus therapy [Seeking Alpha]
2/3
02:30 am
dsnky
DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
Low
Report
DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
2/1
11:44 pm
dsnky
Banking on the long-term potential of oncology drugs: Daiichi Sankyo CFO [CNBC]
Medium
Report
Banking on the long-term potential of oncology drugs: Daiichi Sankyo CFO [CNBC]
1/26
01:33 am
dsnky
Promising New Weight-Loss Pill From South Korea’s Sam Chun Dang Pharm Mints Country’s Newest Billionaire [Forbes]
Low
Report
Promising New Weight-Loss Pill From South Korea’s Sam Chun Dang Pharm Mints Country’s Newest Billionaire [Forbes]
1/22
02:30 am
dsnky
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe [Yahoo! Finance]
Low
Report
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe [Yahoo! Finance]
1/22
01:30 am
dsnky
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe
Low
Report
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe
1/21
02:02 pm
dsnky
Daiichi Sankyo opens Toronto headquarters to fuel Canadian oncology growth [Yahoo! Finance]
Neutral
Report
Daiichi Sankyo opens Toronto headquarters to fuel Canadian oncology growth [Yahoo! Finance]
1/21
08:39 am
dsnky
Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology [Yahoo! Finance]
Low
Report
Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology [Yahoo! Finance]
1/21
08:14 am
dsnky
Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology [Globe and Mail, The (Toronto, Canada)]
Low
Report
Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology [Globe and Mail, The (Toronto, Canada)]
1/21
08:00 am
dsnky
Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology
Low
Report
Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology
1/21
08:00 am
dsnky
Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology
Low
Report
Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology
1/21
08:00 am
dsnky
Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology
Low
Report
Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology
1/19
02:40 am
dsnky
ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer [Yahoo! Finance]
Medium
Report
ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer [Yahoo! Finance]
1/19
02:30 am
dsnky
ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
Medium
Report
ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
1/13
07:00 am
dsnky
TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY® Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
Medium
Report
TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY® Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
1/9
03:42 am
dsnky
Allegro to start production of osteoarthritis hydrogel as it prepares for clinical trials [Yahoo! Finance]
Low
Report
Allegro to start production of osteoarthritis hydrogel as it prepares for clinical trials [Yahoo! Finance]
1/8
01:57 am
dsnky
Organon Enters into a Commercialization Agreement for Daiichi Sankyo's Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway [Yahoo! Finance]
Low
Report
Organon Enters into a Commercialization Agreement for Daiichi Sankyo's Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway [Yahoo! Finance]
1/7
03:02 am
dsnky
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe [Yahoo! Finance]
Low
Report
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe [Yahoo! Finance]
1/7
02:30 am
dsnky
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe
Low
Report
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe
12/22
02:43 am
dsnky
DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer [Yahoo! Finance]
Low
Report
DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer [Yahoo! Finance]
12/22
02:30 am
dsnky
DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer
Low
Report
DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer
12/22
02:30 am
dsnky
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer
Low
Report
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer
12/21
11:56 pm
dsnky
Asian Market Stocks That May Be Trading Below Estimated Value In December 2025 [Yahoo! Finance]
Low
Report
Asian Market Stocks That May Be Trading Below Estimated Value In December 2025 [Yahoo! Finance]
12/21
05:46 pm
dsnky
3 Asian Stocks That Investors Might Be Undervaluing By Up To 35.8% [Yahoo! Finance]
Low
Report
3 Asian Stocks That Investors Might Be Undervaluing By Up To 35.8% [Yahoo! Finance]